278 related articles for article (PubMed ID: 21426334)
1. Clinical experience with generic levetiracetam in people with epilepsy.
Chaluvadi S; Chiang S; Tran L; Goldsmith CE; Friedman DE
Epilepsia; 2011 Apr; 52(4):810-5. PubMed ID: 21426334
[TBL] [Abstract][Full Text] [Related]
2. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
Bosak M; Słowik A; Turaj W
Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836
[TBL] [Abstract][Full Text] [Related]
3. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
[TBL] [Abstract][Full Text] [Related]
4. Brand name to generic substitution of levetiracetam in patients with epilepsy.
Gha-Hyun L; Dae SJ
Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
[TBL] [Abstract][Full Text] [Related]
5. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
6. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
7. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
Vari MS; Pinto F; Mencaroni E; Giudizioso G; Minetti C; La Neve A; Francavilla T; Piccioli M; Striano S; del Gaudio L; Tovo P; Striano P; Verrotti A
Clin Drug Investig; 2016 Jan; 36(1):87-91. PubMed ID: 26507620
[TBL] [Abstract][Full Text] [Related]
8. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after switching to generic levetiracetam - A prospective comparative study.
Olsson P; Reimers A; Källén K
Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
[TBL] [Abstract][Full Text] [Related]
10. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures.
Fitzgerald CL; Jacobson MP
Ann Pharmacother; 2011 May; 45(5):e27. PubMed ID: 21521860
[TBL] [Abstract][Full Text] [Related]
11. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
[TBL] [Abstract][Full Text] [Related]
13. Switch From Originator to Equivalent Drug in the Era of Generic Antiepileptic Drugs: Study of Keppra Versus Epitiram Clinical Equivalence.
Fanella M; Morano A; Fattouch J; Albini M; Basili LM; Casciato S; Manfredi M; Giallonardo AT; Di Bonaventura C
Clin Neuropharmacol; 2017; 40(6):239-242. PubMed ID: 28976412
[TBL] [Abstract][Full Text] [Related]
14. Seizure risk in brain tumor patients with conversion to generic levetiracetam.
Armstrong TS; Choi S; Walker J; Gilbert MR
J Neurooncol; 2010 May; 98(1):137-41. PubMed ID: 19936624
[TBL] [Abstract][Full Text] [Related]
15. Is the anticonvulsant activity of levetiracetam dose-dependent?
Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
[TBL] [Abstract][Full Text] [Related]
16. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Rhee SJ; Shin JW; Lee S; Moon J; Kim TJ; Jung KY; Park KI; Lee ST; Jung KH; Yu KS; Jang IJ; Chu K; Lee SK
Epilepsy Res; 2017 May; 132():8-14. PubMed ID: 28279893
[TBL] [Abstract][Full Text] [Related]
18. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
19. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study.
Trimboli M; Russo E; Mumoli L; Tripepi G; Fortunato F; Mastroianni G; Abate F; De Sarro G; Gambardella A; Labate A
Eur J Neurol; 2018 Apr; 25(4):666-671. PubMed ID: 29322654
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam monotherapy for elderly patients with epilepsy.
Alsaadi TM; Koopmans S; Apperson M; Farias S
Seizure; 2004 Jan; 13(1):58-60. PubMed ID: 14741184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
